Musa Mohamed Babiker, Osman Elmahi Osman Kamal, Modber Mohamed Abdul Kareem Adam, Abuelgasim Mohammed Yagoub Fatima Elbasri, Elkabashi Dafallah Alaa Abusufian, Musa Shuaibu Saidu, Kangwerema Allan, Nzeribe Emmanuella, Mohamed Alanood Elnaeem, Mohamed Nora Alnaeem, Ullah Irfan, Lucero-Prisno Don Eliseo
Faculty of Pharmacy, Omdurman Islamic University, Khartoum, Sudan.
Faculty of Medicine, Ibn Sina University, Khartoum, Sudan.
Public Health Pract (Oxf). 2021 Nov;2:100205. doi: 10.1016/j.puhip.2021.100205. Epub 2021 Oct 18.
The first COVID-19 case in Sudan was announced on March 13th, 2020. 1835 deaths were recorded as of February 7th, 2021. 800,000 doses of the Oxford-AstraZeneca vaccine were allocated to Sudan through COVAX in March 2021. However, multiple challenges exist in vaccinating the Sudanese population, ranging from an inadequate cold chain system to low acceptance rates of COVID-19 vaccination among the Sudanese population. Economic crises, high inflation rates and long-standing economic sanctions have also negatively impacted the healthcare system in Sudan as a result of deprivation of access to research and development funding.
苏丹的首例新冠病毒肺炎病例于2020年3月13日公布。截至2021年2月7日，有1835人死亡。2021年3月，通过新冠疫苗全球获得机制（COVAX）向苏丹分配了80万剂牛津-阿斯利康疫苗。然而，在为苏丹民众接种疫苗方面存在多重挑战，从冷链系统不完善到苏丹民众对新冠疫苗接种的接受率较低。经济危机、高通货膨胀率和长期的经济制裁，也因无法获得研发资金而对苏丹的医疗系统产生了负面影响。
